Laventair Ellipta (Umeclidinium Bromide, Vilanterol)

Umeclidinium bromide blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. Vilanterol stimulates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. Together they produce a complementary, long‑lasting bronchodilatory effect that helps keep the airways open.

The dosing regimen is determined by the prescribing clinician based on the patient’s condition and response. Typically, the medication is administered once daily via the Ellipta inhaler, but the exact number of inhalations and any dose adjustments are individualized by the healthcare professional.

Limited clinical data are available for use in pregnancy and lactation. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Laventair Ellipta combines a LAMA and a LABA in a single inhaler, offering the convenience of one device and once‑daily dosing. Compared with separate LAMA and LABA inhalers, it reduces the number of devices a patient must manage. Relative to other fixed‑dose combos such as tiotropium/olodaterol, the pharmacologic profile is similar, but device preference and individual response may differ.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and extreme heat. Do not expose the device to freezing temperatures. If the inhaler has been dropped or appears damaged, replace it to ensure proper dosing.

The medication is delivered via the Ellipta inhaler. The patient opens the device, exhales fully away from the mouthpiece, places the mouthpiece between the lips, and inhales forcefully and deeply. After inhalation, the patient should hold their breath for a few seconds, then close the inhaler. The device is designed for once‑daily use.

Serious adverse events include paradoxical bronchospasm, which can cause sudden worsening of breathing, and cardiovascular effects such as tachycardia or arrhythmias. Severe hypersensitivity reactions, including anaphylaxis and angioedema, may also occur. Patients should seek immediate medical attention if they experience any of these symptoms.

Laventair Ellipta is contraindicated in individuals with a known hypersensitivity to umeclidinium, vilanterol, or any component of the inhaler. It should also be avoided in patients experiencing an acute severe COPD exacerbation that requires immediate medical intervention, and in those for whom β2‑agonists are contraindicated due to cardiac conditions.